Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul;210(1):154-161.
doi: 10.1097/JU.0000000000003481. Epub 2023 Apr 30.

Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial

Thomas A Masterson  1 , Manuel Molina  1 , Braian Ledesma  1 , Isaac Zucker  1 , Russell Saltzman  1 , Emad Ibrahim  1 , Sunwoo Han  2 , Isildinha M Reis  2   3 , Ranjith Ramasamy  1
Affiliations
Randomized Controlled Trial

Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial

Thomas A Masterson et al. J Urol. 2023 Jul.

Abstract

Purpose: We assessed the safety and efficacy of 2 injections of platelet-rich plasma for treating mild to moderate erectile dysfunction by conducting a prospective, randomized, double-blind, placebo-controlled clinical trial.

Materials and methods: Men with mild to moderate erectile dysfunction (International Index of Erectile Function scores 11-25) were randomized to receive either 2 injections of platelet-rich plasma or placebo separated by 1 month. Primary outcome was percentage of men meeting minimum clinically important difference at 1 month after the second injection. Secondary outcomes were change in International Index of Erectile Function at 1, 3, and 6 months, and changes in penile vascular parameters and adverse events at 6 months.

Results: We randomized 61 men: 28 into platelet-rich plasma and 33 into placebo. There was no difference between groups in percentage of men meeting minimum clinically important difference at 1 month: 14 (58.3%) in platelet-rich plasma vs 15 (53.6%) in placebo (P = .730). Mean International Index of Erectile Function-Erectile Function domain changed from 17.4 (95% CI 15.8-19.0) to 21 (17.9-24.0) at 1 month in men receiving platelet-rich plasma, vs 18.6 (17.3-19.8) to 21.6 (19.1-24.1) in the placebo group; however, there was no significant difference between groups (P = .756). There were no major adverse events and only 1 minor adverse event in each group. There were no changes in penile Doppler parameters from baseline to 6 months.

Conclusions: The results of our prospective, double-blind, randomized, placebo-controlled clinical trial suggest that 2 injections of intracavernosal platelet-rich plasma separated by 1 month in men with mild to moderate erectile dysfunction is safe, but we found no difference in efficacy between platelet-rich plasma and placebo.

Keywords: clinical trial; erectile dysfunction; platelet-rich plasma.

PubMed Disclaimer

Conflict of interest statement

COMPETING INTERESTS

The authors declare no competing interests.

Figures

Figure 1.
Figure 1.
Patient flow diagram
Figure 2.
Figure 2.
Estimated IIEF-EF score means with corresponding 95% confidence intervals from longitudinal data analysis. Asterisks (*) indicate statistically significant difference between baseline and a specific follow-up time in each group (P<0.05). There were no significant differences between groups at any visit (P>0.05).
See this image and copyright information in PMC

Comment in

References

    1. Derby CA, et al., Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study. Int J Impot Res, 2000. 12(4): p. 197–204. - PubMed
    1. Burnett AL, et al., Erectile Dysfunction: AUA Guideline. J Urol, 2018. 200(3): p. 633–641. - PubMed
    1. Kim SC, et al., Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients. Int J Impot Res, 2014. 26(3): p. 87–93. - PMC - PubMed
    1. Carvalheira AA, et al., Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med, 2012. 9(9): p. 2361–9. - PubMed
    1. Baria M, et al., Cellular Components and Growth Factor Content of Platelet-Rich Plasma With a Customizable Commercial System. Am J Sports Med, 2019. 47(5): p. 1216–1222. - PubMed

Publication types